Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31084193)

  • 1. IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
    Xing Z; Zhang H; She D; Lin Y; Zhou X; Zeng Z; Cao D
    Acta Radiol; 2019 Dec; 60(12):1663-1672. PubMed ID: 31084193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive prediction of p53 and Ki-67 labelling indices and O-6-methylguanine-DNA methyltransferase promoter methylation status in adult patients with isocitrate dehydrogenase wild-type glioblastomas using diffusion-weighted imaging and dynamic susceptibility contrast-enhanced perfusion-weighted imaging combined with conventional MRI.
    Xing Z; Huang W; Su Y; Yang X; Zhou X; Cao D
    Clin Radiol; 2022 Aug; 77(8):e576-e584. PubMed ID: 35469666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
    Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
    Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Assessment of
    Xing Z; Yang X; She D; Lin Y; Zhang Y; Cao D
    AJNR Am J Neuroradiol; 2017 Jun; 38(6):1138-1144. PubMed ID: 28450436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI.
    Lin Y; Xing Z; She D; Yang X; Zheng Y; Xiao Z; Wang X; Cao D
    Neuroradiology; 2017 Jun; 59(6):555-562. PubMed ID: 28474187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
    Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
    Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging.
    Yang X; Xing Z; She D; Lin Y; Zhang H; Su Y; Cao D
    BMC Med Imaging; 2022 May; 22(1):105. PubMed ID: 35644621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas.
    Lu J; Li X; Li H
    Magn Reson Imaging; 2021 Nov; 83():189-195. PubMed ID: 34506909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI.
    Chawla S; Wang S; Mohan S; Nasrallah M; Verma G; Brem S; O'Rourke DM; Wolf RL; Poptani H; Nabavizadeh SA
    J Magn Reson Imaging; 2019 Jan; 49(1):184-194. PubMed ID: 29676844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation between supratentorial pilocytic astrocytoma and extraventricular ependymoma using multiparametric MRI.
    Zhou X; Su Y; Huang W; Lin X; Xing Z; Cao D
    Acta Radiol; 2022 Dec; 63(12):1661-1668. PubMed ID: 34709088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Conventional, Diffusion, and Perfusion MRI Between Low-Grade and Anaplastic Extraventricular Ependymoma.
    Xing Z; Zhou X; Xiao Z; She D; Wang X; Cao D
    AJR Am J Roentgenol; 2020 Oct; 215(4):978-984. PubMed ID: 32809860
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive role of magnetic resonance imaging in the distinction of isocitrate dehydrogenase (IDH) mutant grade 4 astrocytomas versus glioblastomas.
    Halefoglu AM; Camurcuoglu E; Tanik C; Kizilkaya O; Yilmaz A
    Acta Radiol; 2023 Jun; 64(6):2074-2086. PubMed ID: 37038636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can Dynamic Susceptibility Contrast Perfusion Imaging be Utilized to Detect Isocitrate Dehydrogenase Gene Mutation in Gliomas?
    Kilincer A; Cebeci H; Seher N; Durmaz MS; Uysal E; Sahinoglu M; Koktekir E; Karabagli H; Karabagli P; Paksoy Y
    Turk Neurosurg; 2022; 32(5):826-833. PubMed ID: 35713257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network.
    Choi KS; Choi SH; Jeong B
    Neuro Oncol; 2019 Sep; 21(9):1197-1209. PubMed ID: 31127834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
    Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
    J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours.
    Xiong J; Tan W; Wen J; Pan J; Wang Y; Zhang J; Geng D
    Eur Radiol; 2016 Jun; 26(6):1705-15. PubMed ID: 26396108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
    Patel SH; Batchala PP; Muttikkal TJE; Ferrante SS; Patrie JT; Fadul CE; Schiff D; Lopes MB; Jain R
    J Neurooncol; 2021 May; 152(3):523-531. PubMed ID: 33661425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.